|
1
|
Krogstad P, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Brown E, Denson K, Graham B, Hovind L, Sise T, Teppler H, Mathiba SR, Fairlie L, Winckler JL, Slade G, Meyers T. Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. J Pediatric Infect Dis Soc 2021; 10:201-204. [PMID: 32448902 PMCID: PMC7996637 DOI: 10.1093/jpids/piaa039] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Accepted: 04/09/2020] [Indexed: 11/14/2022]
Abstract
Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB. CLINICAL TRIALS REGISTRATION NCT01751568.
Collapse
Affiliation(s)
- Paul Krogstad
- Departments of Pediatrics and Molecular and Medical Pharmacology, David Geffen School of Medicine at Los Angeles, Los Angeles, California, USA
| | - Pearl Samson
- Statistical and Data Management Center, Frontier Science Foundation/Harvard T.H. Chan School of Public Health Boston, Massachusetts, USA
| | - Edward P Acosta
- Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Jack Moye
- Maternal and Pediatric Infectious Disease Branch, Division of Extramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA
| | - Ellen Townley
- Columbus Technologies and Services, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
| | | | | | - Kayla Denson
- Frontier Science Foundation, Inc, Amherst, New York, USA
| | - Bobbie Graham
- Frontier Science Foundation, Inc, Amherst, New York, USA
| | - Laura Hovind
- Frontier Science Foundation, Inc, Amherst, New York, USA
| | - Thucuma Sise
- Columbus Technologies and Services, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
| | - Hedy Teppler
- Global Clinical Development - Infectious Diseases, Merck & Co, Inc, Kenilworth, New Jersey, USA
| | - Sisinyana Ruth Mathiba
- Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
| | - Lee Fairlie
- Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Jana L Winckler
- Desmond Tutu TB Centre, Department of Paediatrics, Stellenbosch University, Cape Town South Africa
| | - Gretchen Slade
- Department of Paediatrics and Child Health, Family Clinical Research Unit, Stellenbosch University, Cape Town, South Africa
| | - Tammy Meyers
- Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | | |
Collapse
|